This is half of a two-part debate — read the opposing argument.  Following the introduction of infliximab in 1998, two additional tumor necrosis factor antagonists (i.e., adalimumab, certolizumab pegol), the anti- integrin vedolizumab and ustekinumab (a monoclonal directed to interleukin 12 and 23) were approved for the management of inflammatory bowel disease. Biologics have greatly […]

Quick Hits

With the recent approvals of infliximab biosimilars, CT-P13 and SB2, and adalimumab biosimilar, ABP 501, by the U.S. FDA, the landscape of available anti-tumor necrosis factor (TNF) therapies for the treatment of inflammatory bowel disease (IBD) is changing right before our eyes. To understand the implications of this change, it is important to consider several […]